Heyuan Bio's Naxiolen赛 Injection Receives NMPA Acceptance for Pediatric Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Recently, Juventas announced that its core product, Natriolcel Injection (trade name: Yuan Ruida),®）For the treatment of children with relapsed or refractory BCell EmergencyRelapsed/Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL)The listing applicationAccepted by the National Medical Products Administration (NMPA).

Acute Lymphoblastic Leukemia (ALL) is the most common hematologic malignancy in children.Accounting for over 70% of childhood leukemia cases.Moreover, 20%-25% of patients will experience recurrence or primary refractoriness, and the prognosis for this group is extremely poor, especially for those with primary refractoriness.Patient RetentionThe rescue efficiency is only 31%, and the median overall survival (OS) is less than one year.

According to public information, the drug "Najiolun Injection" isThe First CAR-T Drug in China's Leukemia Treatment Field,It is also the first CD19 CAR-T drug in China that is fully independently innovated. The two previously approved indications are: forTreatmentAdult Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaAnd for use inTreatmentAdult Relapsed or Refractory Large B-Cell Lymphoma。

Operation｜Li Muzi